As the world's population is aging, Alzheimer’s disease (AD) has become a big concern
since AD has started affecting younger people and the population of AD patients is increasing
worldwide. It has been revealed that the neuropathological hallmarks of AD are typically characterized
by the presence of neurotoxic extracellular amyloid plaques in the brain, which are surrounded
by tangles of neuronal fibers. However, the causes of AD have not been completely understood yet.
Currently, there is no drug to effectively prevent AD or to completely reserve the symptoms in the
patients. This article reviews the pathological features associated with AD, the recent progress in
research on the drug development to treat AD, especially on the discovery of natural product derivatives
to inhibit Aβ peptide aggregation as well as the design and synthesis of Aβ peptide aggregation
inhibitors to treat AD.
Keywords: Alzheimer's disease, amyloid hypothesis, amyloid β aggregation, amyloid β peptide inhibitors, drug development,
Rights & PermissionsPrintExport